IndyGeneUS Bio
PrivateLast Round
Seed
Jan 12, 2026
Total Funding Raised
$2.28M
Company Overview
IndyGeneUS Bio operates in Healthcare & Life Sciences and is based in Baltimore, Maryland. Its latest recorded funding round was a Seed round in January 2026.
IndyGeneUS Bio is a biotechnology company that operates a clinico-genomic insight engine and a large, blockchain-encrypted bio-repository of African genomic data to advance drug discovery and precision health equity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Data Governance
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IndyGeneUS Bio Comparables
Compare IndyGeneUS Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Syndicate Bio | 86% | |
| Yemaachi Biotechnology | 77% | |
| Variant Bio | 73% |
For institutional investors. Book with your work email.
IndyGeneUS Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jan 12, 2026 | ||||
| Grant | Oct 25, 2024 | ||||
| Accelerator | Dec 20, 2022 | ||||
| Grant | May 12, 2022 | ||||
| Pre Seed | Dec 27, 2021 |
For institutional investors. Book with your work email.
IndyGeneUS Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Majority Ventures | Grant |
| McKesson Ventures | Accelerator |
| IsimoVest Venture Capital Partners | Pre Seed |
| Northpond Ventures | Accelerator |
| McKesson Ventures | Accelerator |
| DownEast Digital | Seed |
| Northpond Ventures | Accelerator |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 3, 2026
Monthly visitors increased 30% MoM, from 389 to 506.
- Aug 17, 2025
Won first place in the Disabled American Veterans Pitch Competition.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 11, 2026
IndyGeneUS Bio has raised nearly $2M in Pre Seed funding and partners with Johnson & Johnson's JLABs and the Aurum Institute to build a blockchain-secured repository of clinical and genomic data focused on African diaspora populations.
For institutional investors. Book with your work email.
IndyGeneUS Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about IndyGeneUS Bio's valuation, stock price, and market status.
Is IndyGeneUS Bio a public or private company?
IndyGeneUS Bio is a private company.
What is the current stock price of IndyGeneUS Bio?
IndyGeneUS Bio is a private company, so its shares have no public market price. Caplight tracks IndyGeneUS Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is IndyGeneUS Bio worth (valuation)?
Valuation information for IndyGeneUS Bio is not publicly available.
Can I buy IndyGeneUS Bio stock?
IndyGeneUS Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was IndyGeneUS Bio's last funding round?
IndyGeneUS Bio's most recent funding round was Seed on January 12, 2026.
Who are the main investors in IndyGeneUS Bio?
Key investors in IndyGeneUS Bio include Baltimore Development Corporation.
Will IndyGeneUS Bio IPO soon?
No public IPO plans have been announced for IndyGeneUS Bio.
How can I track IndyGeneUS Bio secondary market activity?
Caplight tracks bids, offers, and trades in IndyGeneUS Bio's shares on secondary markets.